The role of dosimetry and biological effects in metastatic castration–resistant prostate cancer (mCRPC) patients treated with (223)Ra: first in human study

BACKGROUND: (223)Ra is currently used for treatment of metastatic castration resistant prostate cancer patients (mCRPC) bone metastases with fixed standard activity. Individualized treatments, based on adsorbed dose (AD) in target and non-target tissue, are absolutely needed to optimize efficacy whi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sciuto, Rosa, Rea, Sandra, Ungania, Sara, Testa, Antonella, Dini, Valentina, Tabocchini, Maria Antonella, Patrono, Clarice, Soriani, Antonella, Palma, Valentina, Marconi, Raffaella, Strigari, Lidia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420003/
https://www.ncbi.nlm.nih.gov/pubmed/34488829
http://dx.doi.org/10.1186/s13046-021-02056-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8420003/
https://www.ncbi.nlm.nih.gov/pubmed/34488829
http://dx.doi.org/10.1186/s13046-021-02056-9

Ejemplares similares